Coherus announces US launch of Cimerli (ranibizumab) on 03 October 2022

Sep 19, 2022

Coherus Biosciences announced that it will launch Cimerli™ (interchangeable biosimilar ranibizumab) in the US on 03 October 2022.  Cimerli was approved by the FDA as interchangeable with Genentech/Roche’s Lucentis® and the EMA in August 2022.

Print Page Mail Article